[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"health-effects-ferritin-levels-crp-levels-igg-levels-self-reported-health\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:health-effects-ferritin-levels-crp-levels-igg-levels-self-reported-health":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100634767","cohort-of-repeat-donor-experiences-core-study-100634767",false,"NCT07543965","Cohort of Repeat Donor Experiences (CORE) Study","Associations Between Frequent Plasmapheresis, Biomarkers, and Health Outcomes: A 2-Year National Prospective Cohort Study","CORE","Inclusion Criteria:\n\n* Aged 18-74;\n* Meet health and medical history requirements for being a plasma donor per eCFR::21 CFR 630.10 Subpart B -- General donor eligibility requirements;\n* Willing to provide phone number and mailing address; has access to internet-enabled smartphone device;\n* Plans to remain within local area during study duration; has not donated whole blood within past 12 months;\n* Does not have permanent deferral;\n* Has not donated plasma more than once at a non-participating plasma center;\n* Another member of their household is not enrolled.","ALL","18 Years","74 Years",{"count":21,"type":22},2090,"ESTIMATED","OBSERVATIONAL","The Plasma Protein Therapeutics Association (PPTA) sponsors the Cohort of Repeat Donor Experiences (CORE) Study. This is a prospective, observational cohort study that will follow Source Plasma donors for up to 2 years during the main study (anticipated to begin in summer 2026) and up to 3 months during the pilot launching in mid-March 2026. This study aims to confirm a lack of negative health effects Source Plasma donors may experience as a result of frequent plasmapheresis. The study will use data obtained through self-report surveys for the duration of the study along with periodic whole blood sample collections to test for CRP, ferritin, and IgG.",[26],"Health Effects (Ferritin Levels, CRP Levels, iGg Levels, Self-reported Health)",[28,29,30],"plasma","plasma-derived therapies","pharma","NOT_YET_RECRUITING","2026-04-14",{"date":34,"type":35},"2026-04-22","ACTUAL",{"date":37,"type":22},"2026-04-06",{"date":39,"type":22},"2029-04-30",{"name":41,"class":42},"Westat","OTHER"]